Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: Evidence from a randomised controlled trial in Nepal

Alirol, Emilie; Sharma, Sanjib Kumar; Ghimire, Anup; Poncet, Antoine; Combescure, Christophe; Thapa, Chabilal; Paudel, Vijaya Prasad; Adhikary, Kalidas; Taylor, Walter Robert; Warrell, David; Kuch, Ulrich; Chappuis, François

doi:10.1371/journal.pntd.0005612

Scientific article

English

Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: Evidence from a randomised controlled trial in Nepal

ContributorsAlirol, Emilie; Sharma, Sanjib Kumar; Ghimire, Anup; Poncet, Antoine; Combescure, Christophe

; Thapa, Chabilal; Paudel, Vijaya Prasad; Adhikary, Kalidas; Taylor, Walter Robert; Warrell, David; Kuch, Ulrich; Chappuis, François

Published inPLOS Neglected Tropical Diseases, vol. 11, no. 5, e0005612

Publication date2017

Abstract

Currently, there is inadequate evidence on which to base clinical management of neurotoxic snakebite envenoming, especially in the choice of initial antivenom dosage. This randomised controlled trial compared the effectiveness and safety of high versus low initial antivenom dosage in victims of neurotoxic envenoming.

Keywords

Snakebite
Sudden cardiac death
Snakes
Anaphylaxis
Venoms
Advers events
Nepal
Cobras

Affiliation entities

Research groups

Epidémiologie clinique (115)

Funding

Swiss National Science Foundation - A randomized, double-blind, multi-centre clinical trial of two dose regimens of polyvalent Anti Snake Venom Serum (ASVS) for the treatment of snake bite envenoming in Nepal [131223]

Citation (ISO format)

ALIROL, Emilie et al. Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: Evidence from a randomised controlled trial in Nepal. In: PLOS Neglected Tropical Diseases, 2017, vol. 11, n° 5, p. e0005612. doi: 10.1371/journal.pntd.0005612